Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA Damage Response Alterations and Immune Checkpoint Blockade Outcomes Across Multiple Cancers.

JCO precision oncology - 1 Jun 2026

Ma Tian-Chi, Guo Wen-Heng, Liu De-Min, Li Qian-Jie, Wang Ren-Ci, Wang He-Rong, Li Juan, He Ya-Long, Yin An-An, Lin Wei

Abstract excerpt

PURPOSE: DNA damage response (DDR) alterations have been implicated in immunotherapy efficacy, but their pan-cancer predictive value for immune checkpoint blockade (ICB) remains unclear. We aimed to characterize DDR mutational landscapes and evaluate their ability to predict ICB outcomes across multiple cancer types. MATERIALS AND METHODS: We integrated multiomics data from The Cancer Genome Atlas with...

Topics

Join the communities discussing this publication.

DNA Damage
Immune Checkpoint Inhibitors
Mutation
Neoplasms
Prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 42372205
DOI: 10.1200/PO-25-00810

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA Damage Response Alterations and Immune Checkpoint Blockade Outcomes Across Multiple Cancers.PMID 42372205Read ↗

Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.Semantic proximity Read ↗

Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor typesSemantic proximity Read ↗

Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future PerspectivesSemantic proximity Read ↗

Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing.Semantic proximity Read ↗

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.Semantic proximity Read ↗

Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.Semantic proximity Read ↗

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity Read ↗

Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations.Semantic proximity Read ↗

Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.Semantic proximity Read ↗

Mutational Landscape and Sensitivity to Immune Checkpoint Blockers.Semantic proximity Read ↗

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.Semantic proximity Read ↗

Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a MatchmakerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.